CLDI Calidi Biotherapeutics, Inc. Insider Trading

CEO Eric E Poma purchased 25,000 shares at $2.00 on 2025-08-21; stock now at $1.56, down 96.2% from $40.56 high; cluster of 3 other insiders buying in past 14 days.

CEO Eric E Poma initiated a 25,000-share position at $2.00, acquiring his first holdings in Calidi Biotherapeutics. This purchase occurs within a cluster pattern: 3 other insiders also bought within the past 14 days, suggesting coordinated accumulation by company leadership. The timing coincides with severe price deterioration—the stock trades at $1.56, down 96.2% from the 52-week high of $40.56 and down 82.2% over the past 30 days, indicating acute market distress. Against a backdrop of negative net income of $-5.7M and a market cap of only $5.3M, the cluster buy pattern and CEO's initiation of a direct stake warrant scrutiny of whether this reflects material information asymmetry or management's assessment of intrinsic value relative to distressed pricing.

Director Schoeneck buys 75.0K shares of CLDI at $2.00 amid 96.2% decline from 52-week high; 3-insider cluster buy in loss-making biotech.

Director James A Schoeneck purchased 75,000 shares at $2.00 on 2025-08-21, representing a 6613.8% increase in his holdings from 1,134 to 76,134 shares, while the stock trades at $1.56—96.2% below its 52-week high of $40.56. The transaction occurs within a cluster of 3 other insider purchases over the past 14 days, suggesting coordinated accumulation despite the company's unprofitable position (net income: $-5,715,000.00) and market-cap distress ($5,345,193.36). Schoeneck's historical cross-ticker track record shows 3 prior buys with average 90-day returns of +1390.0% and 100% win rate, though that pattern does not establish predictive power at this specific ticker. The confluence of severe equity collapse, unprofitability, multi-insider cluster activity, and a substantial position increase (from minimal to material) warrants examination of whether new information or restructuring dynamics underlie the coordinated buying.

CFO Jackson buys 2.5K shares at $2.00; stock down 96.2% from $40.56 high; 3 other insiders bought in past 14 days

Jackson Andrew C., CFO of Calidi Biotherapeutics, purchased 2,500 shares at $2.00 on 2025-08-21, representing his first equity position in the company. The purchase occurs after a severe equity drawdown: the stock is currently at $1.56, down -96.2% from its 52-week high of $40.56 and down -82.2% over the past 30 days. Notably, three other insiders also purchased shares within the past 14 days, forming a cluster buy pattern. The company remains unprofitable with a net income of $-5.7M over its most recent full fiscal year, and its market capitalization stands at $5.3M, raising questions about whether the cluster purchases reflect conviction or are driven by other factors in a distressed financial context.

Director Scott Leftwich bought 125,000 shares of CLDI at $2.00 amid -96.2% drawdown from 52-week high; 3 insiders buying in 14 days.

Scott Leftwich purchased 125,000 shares for $250,000.00, increasing his holdings by 2212.4% from 5,650 to 130,650 shares. The transaction occurred when the stock traded at $2.00, a price -96.2% below the 52-week high of $40.56 and down -82.2% over the past 30 days. A cluster pattern shows 3 other insiders also bought within the past 14 days, suggesting coordinated insider accumulation during a period of severe price decline. The company posted net income of $-5,715,000.00 and has a market cap of $5,345,193.36, indicating unprofitability and a small public equity base, making insider buying behavior a material signal in a distressed context.